BR0210266A - Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases - Google Patents

Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases

Info

Publication number
BR0210266A
BR0210266A BR0210266-8A BR0210266A BR0210266A BR 0210266 A BR0210266 A BR 0210266A BR 0210266 A BR0210266 A BR 0210266A BR 0210266 A BR0210266 A BR 0210266A
Authority
BR
Brazil
Prior art keywords
composition
lipase inhibitor
obesity treatment
preparing
pharmaceutical composition
Prior art date
Application number
BR0210266-8A
Other languages
English (en)
Other versions
BRPI0210266B1 (pt
Inventor
Karsten Maeder
Rainer Eugen Martin
Susanne Raab
Lukas Christoph Scheibler
Thomas Schindler
Marco Schroeder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0210266(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0210266A publication Critical patent/BR0210266A/pt
Publication of BRPI0210266B1 publication Critical patent/BRPI0210266B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA QUE COMPREENDE UM INIBIDOR DE LìPASES, PROCESSO PARA PREPARAR ESSA COMPOSIçãO, CONJUNTO PARA O TRATAMENTO DE OBESIDADE, UTILIZAçãO DA COMPOSIçãO, PROCESSO DE TRATAMENTO DE OBESIDADE E INIBIDOR DE LìPASES". A presente invenção refere-se a uma composição farmacêutica que compreende um inibidor de lípases, preferentemente orlistat, dotado de um ponto de fusão de <242>37<198>C, um éster de ácido graxo de sacarina em que o éster de ácido graxo de sacarina é um mono-, di-, tri- ou tetra-éster e, opcionalmente, um ou mais excipientes farmaceuticamente aceitáveis.
BRPI0210266A 2001-06-06 2002-05-29 composição farmacêutica que compreende um inibidor de lipases e um éster de ácido graxo de sacarose, processo para preparar essa composição e utilização da composição BRPI0210266B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01113793 2001-06-06
PCT/EP2002/005889 WO2002098412A1 (en) 2001-06-06 2002-05-29 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester

Publications (2)

Publication Number Publication Date
BR0210266A true BR0210266A (pt) 2004-07-20
BRPI0210266B1 BRPI0210266B1 (pt) 2016-01-26

Family

ID=8177654

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210266A BRPI0210266B1 (pt) 2001-06-06 2002-05-29 composição farmacêutica que compreende um inibidor de lipases e um éster de ácido graxo de sacarose, processo para preparar essa composição e utilização da composição

Country Status (40)

Country Link
US (4) US20030027786A1 (pt)
EP (1) EP1399152B1 (pt)
JP (2) JP4261337B2 (pt)
KR (1) KR100753729B1 (pt)
CN (1) CN1514725B (pt)
AR (1) AR034355A1 (pt)
AT (1) ATE356622T1 (pt)
AU (1) AU2002257817B2 (pt)
BG (1) BG66346B1 (pt)
BR (1) BRPI0210266B1 (pt)
CA (1) CA2448030C (pt)
CO (1) CO5540293A2 (pt)
CY (1) CY1107641T1 (pt)
CZ (1) CZ299948B6 (pt)
DE (1) DE60218845T2 (pt)
DK (1) DK1399152T3 (pt)
EC (1) ECSP034871A (pt)
ES (1) ES2282415T3 (pt)
GT (1) GT200200106A (pt)
HK (1) HK1067312A1 (pt)
HR (1) HRP20030983B1 (pt)
HU (1) HU230405B1 (pt)
IL (2) IL158908A0 (pt)
JO (1) JO2455B1 (pt)
MA (1) MA27031A1 (pt)
ME (1) ME00579B (pt)
MX (1) MXPA03011191A (pt)
MY (1) MY161871A (pt)
NO (1) NO328006B1 (pt)
NZ (1) NZ529630A (pt)
PA (1) PA8546701A1 (pt)
PE (1) PE20030230A1 (pt)
PL (1) PL215266B1 (pt)
PT (1) PT1399152E (pt)
RS (1) RS50713B (pt)
RU (1) RU2271808C2 (pt)
SI (1) SI1399152T1 (pt)
SK (1) SK287602B6 (pt)
WO (1) WO2002098412A1 (pt)
ZA (1) ZA200309007B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
SI1897558T1 (sl) * 2005-06-09 2014-03-31 Norgine Bv Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
US20070111914A1 (en) * 2005-11-16 2007-05-17 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Environmentally friendly laundry method and kit
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR2994386B1 (fr) * 2012-08-07 2016-06-24 Thorel Jean-Noel Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
AU2016342375B2 (en) 2015-10-23 2022-03-17 Erx Pharmaceuticals Inc Analogs of celastrol
CN113151373B (zh) * 2021-03-09 2023-07-04 武汉臻治生物科技有限公司 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用
KR102637596B1 (ko) 2022-03-18 2024-02-19 (주)보노보씨 기능성 목공교구

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965133A1 (de) 1969-12-27 1971-07-22 Merck Patent Gmbh Verfahren zur Herstellung pharmazeutischer Zubereitungen
US4148874A (en) * 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
NL8600050A (nl) 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
EP0271963B1 (en) * 1986-12-19 1993-07-21 The Procter & Gamble Company Food compositions with superior blood cholesterol lowering properties
JP2748597B2 (ja) 1989-09-28 1998-05-06 三菱化学株式会社 食品劣化抑制剤
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
JP3112473B2 (ja) 1990-10-18 2000-11-27 オリンパス光学工業株式会社 屈折率分布型光学素子の製造方法
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
TR200100472T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
CN1170534C (zh) 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
AU1031500A (en) 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
AU1238101A (en) 1999-10-29 2001-05-14 John Jason Gentry Mullins Oxetanone derivatives
PL203804B1 (pl) * 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem
DE60110232T2 (de) 2000-07-28 2006-01-19 F. Hoffmann-La Roche Ag Neue verwendung von lipase-inhibitoren
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6534097B1 (en) * 2002-07-11 2003-03-18 Betty Baggott Pest repellent

Also Published As

Publication number Publication date
PE20030230A1 (es) 2003-03-17
MA27031A1 (fr) 2004-12-20
EP1399152B1 (en) 2007-03-14
ME00579A (en) 2011-12-20
ZA200309007B (en) 2005-04-26
BG108421A (en) 2005-02-28
RU2271808C2 (ru) 2006-03-20
WO2002098412A1 (en) 2002-12-12
US20030027786A1 (en) 2003-02-06
PL215266B1 (pl) 2013-11-29
JP4261337B2 (ja) 2009-04-30
CY1107641T1 (el) 2013-04-18
US8039508B2 (en) 2011-10-18
RU2003136728A (ru) 2005-05-20
NO20035318D0 (no) 2003-11-28
JO2455B1 (en) 2008-10-09
BG66346B1 (bg) 2013-08-30
KR100753729B1 (ko) 2007-08-30
SK287602B6 (sk) 2011-03-04
RS50713B (sr) 2010-06-30
AR034355A1 (es) 2004-02-18
NO328006B1 (no) 2009-11-09
US20050101562A1 (en) 2005-05-12
RS96003A (en) 2006-10-27
CN1514725A (zh) 2004-07-21
HRP20030983B1 (en) 2011-10-31
SK16092003A3 (sk) 2004-05-04
NZ529630A (en) 2006-05-26
DK1399152T3 (da) 2007-06-18
ECSP034871A (es) 2004-01-28
MY161871A (en) 2017-05-15
CN1514725B (zh) 2010-04-21
BRPI0210266B1 (pt) 2016-01-26
CZ299948B6 (cs) 2009-01-07
EP1399152A1 (en) 2004-03-24
PT1399152E (pt) 2007-06-05
CZ20033525A3 (cs) 2004-04-14
IL158908A0 (en) 2004-05-12
US20130079391A1 (en) 2013-03-28
PA8546701A1 (es) 2003-01-24
PL366890A1 (en) 2005-02-07
DE60218845T2 (de) 2008-01-03
SI1399152T1 (sl) 2007-08-31
JP2004532271A (ja) 2004-10-21
HUP0401208A3 (en) 2008-04-28
HRP20030983A2 (en) 2005-08-31
GT200200106A (es) 2003-02-11
ES2282415T3 (es) 2007-10-16
US20110301231A1 (en) 2011-12-08
AU2002257817B2 (en) 2005-08-18
DE60218845D1 (de) 2007-04-26
MXPA03011191A (es) 2004-02-26
CA2448030C (en) 2009-11-24
US8343543B2 (en) 2013-01-01
IL158908A (en) 2008-08-07
CA2448030A1 (en) 2002-12-12
HU230405B1 (hu) 2016-04-28
ATE356622T1 (de) 2007-04-15
HUP0401208A2 (hu) 2004-11-29
JP2009108076A (ja) 2009-05-21
CO5540293A2 (es) 2005-07-29
ME00579B (me) 2011-12-20
KR20040010689A (ko) 2004-01-31
HK1067312A1 (en) 2005-04-08

Similar Documents

Publication Publication Date Title
BR0210266A (pt) Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
BR0010555A (pt) Inibidores de neuraminidases
BR0112799A (pt) Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BR9401482A (pt) 1H-Indol-3-acetamida, formulação farmacêutica, utilização de um composto e processo para a preparação de 1h-indol-3-acetamida
BR0016164A (pt) Composto,composição farmacêutica, uso de um composto, e, métodos para o tratamento e/ou profilaxia de asma, alergia, artrite, incluindo artrite reumatóide e espondiloartrite, gota, ateroesclerose, doença intestinal inflamatória crÈnica (doença de crohn), distúrbios dermatológicos inflamatórios e proliferativos, psorìase, dermatite atópica, uveìte, choque séptico, aids e osteoporose e para o tratamento de acne
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
BR9712530A (pt) Inibidores de ésteres de asparato de enzima de conversão de interleucina-1beta
BRPI0607555A2 (pt) inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
BR0113669A (pt) Inibidores da desacetilase
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
BRPI0409227B8 (pt) &#34;composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)&#34;
BR9812010A (pt) Determinados ácidos 5-alquil-2-arilaminofenilacéticos e derivados
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
BRPI0414299A (pt) composições farmacêuticas de liberação modificada de modafinil
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd
BRPI0510451A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização
BR0208999A (pt) Processo para a preparação de ácido de cefpodoxima
BR0111767A (pt) Composições analgésicas e anti-inflamatórias contendo inibidores de cox-2, seu uso e método para potencializar um composto analgésico
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.